Elger B, Hornberger W, Schwarz M, et al. Ancrod reduces intracerebral hemorrhage quantified in vivo by magnetic resonance imaging in rats[J]. J Stroke Cerebrovasc Dis,1998, 7(1): 10-16.
[2]
Yu X, Li Z, Xia X, et al. Expression and purification of ancrod, an anticoagulant drug, in Pichia pastoris[J]. Protein Expr Purif, 2007, 55(2): 257-261.
[3]
Tan N H. Isolation and characterization of the thrombin-like enzyme from cryptelytrops purpureomaculatus venom[J]. Comp Biochem Physiol C Toxicol Pharmacol, 2010, 151(1): 131-136.
[4]
Levy D E, Trammel J, Wasiewski W W, et al. Ancrod for acute ischemic stroke: a new dosing regimen derived from analysis of prior ancrod stroke studies[J]. J Stroke and Cerebrovasc Dis, 2009, 18(1): 23-27.
[5]
高晶，刘秀琴，郭玉璞. 降纤制剂的研究和临床应用新进展[J]. 中华神经科杂志,2001,34(5):305-307.Gao Jing, Liu Xiuqin, Guo Yupu, et al. The progress of research and clinical application of difibration preparation[J]. Chinese Journal of Neurology, 2001, 34(5): 305-307（in Chinese）.
[6]
Burkhart W, Smith G F, Su JL, et al. Amino acid sequence determination of ancrod, the Thrombin-like α-fibrinogenase from the venom of akistrodon rhodostoma[J]. FEBS Lett,1992, 297(3): 297-301.
[7]
Liu S, Marder V J, Levy D E, et al. Ancrod and fibrin formation: perspectives on mechanisms of action[J]. Stroke, 2011, 42(11): 3277-3280.
[8]
Suqai K, Imamura Y, Mihashi S, et al. Plasma levels and urinary excretion of batroxobin and its defibrinogenating effects in various animal species[J]. J Toxicol Sci, 1986, 11(2): 135-143.
[9]
Suqai K, Imamura Y, Mihashi S, et al. Metabolic fate of 125I-labeled Batroxobin in rats and dogs[J]. J Toxicol Sci, 1986, 11(3): 155-167.
[10]
卢海波，戴德银，刘立立. 五种蛇毒制剂的临床应用与警示[J]. 现代医药卫生,2012,28(16):2495-2496.Lu Haibo, Dai Deyin, Liu Lili, et al. The clinical application and caution of five preparation of snake[J]. Journal of Modern Medicine and Health, 2012, 28(16): 2495-2496（in Chinese）.
[11]
Liu M, Wu B, Wang W Z, et al. Stroke in China:epidemiology, prevention, and management strategies[J]. Lancet Neurol, 2007, 6(5): 456-464.
[12]
王俊虎，蒋翠花，江骁.131I标记番泻苷A在正常小鼠体内分布和评价心肌活性研究[J]. 同位素,2013,26(2):98-103.Wang Junhu, Jiang Cuihua, Jiang Xiao, et al. Distribution and evaluation of myocardial viability studies of131I-labeled Sennoside A in normal mice[J]. Isotope, 2013, 26(2): 98-103（in Chinese）.
[13]
梁积新，李洪玉，向学琴. 神经肽类似物DOTA-Substance P的177Lu标记及其生物分布[J]. 同位素,2012,25(2):65-70.Liang Jixin, Li Hongyu, Xiang Xueqin, et al. 177Lu-labeled DOTA-Substance P of neuropeptide analogues and its distribution[J]. Isotope, 2012, 25(2): 65-70（in Chinese）.
[14]
姜国华，刘忠敏. 同位素示踪法研究125I-NGF在小鼠体内的吸收、分布及排泄[J]. 现代仪器,2012,18(1):10-13.Jiang Guohua, Liu Zhongmin. The absorption, distribution, and excretion studies of125I-NGF by using isotopic tracer method in mice[J]. 2012, 18(1): 10-13（in Chinese）.
